At SeromYx, we share the latest news, publications, and event highlights as we advance Fc effector function science across vaccines and antibody therapeutics. Stay connected to follow our research, partnerships, and industry presence.
Research has shed light on how a new type of antibody treatment reactivates patients’ immune cells to fight ovarian cancer. The research, from the group of Professor Sophia Karagiannis at King’s College London, could help to better understand the responses of patients who receive this type of therapy.
Woburn, MA, February 5th, 2025 — SeromYx Systems, Inc., a global leader in high-throughput antibody characterization and Systems Serology services, today announced the retirement of Chief Executive Officer, Mr. Piers Whitehead, a co-founder of the company,...
Woburn, MA / Newark, DE – October 1st, 2024 - SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the...
Woburn, MA / Newark, DE – October 1st, 2024 - SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the...
Woburn, MA, September, 25th, 2024 – SeromYx Systems, a leading provider of GCLP Systems Serology and Antibody characterization services, is excited to announce a new immunobiology collaboration to better understand Post-Acute Sequelae of SARS-CoV-2...
